Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty
3期
已完成
NCT05558410
| 适应症 | Acute Pain |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Vertex Pharmaceuticals Incorporated |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 1,118 人 |
|---|
| 干预（药物） | Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP) |
|---|
| 开始日期 | 2022年10月10日 |
|---|
| 完成日期 | 2023年8月25日 |
|---|
| 结果公布日 | 2025年7月1日 |
|---|
摘要
The purpose of this study was to evaluate the efficacy and safety of Suzetrigine (SUZ) in treating acute pain after an abdominoplasty.
Time-weighted Sum of the Pain Intensity Difference (SPID) as Recorded on a Numeric Pain Rating Scale (NPRS) From 0 to 48 Hours (SPID48) SUZ Compared to Placebo
0 to 48 hours After First Dose of Study Drug · units on a scale
| Placebo | 70.1 ± 6.1 units on a scale |
|---|
| Suzetrigine (SUZ) | 118.4 ± 4.3 units on a scale |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。